Midostaurin is a multikinase inhibitor that inhibits the protein produced by c-kit, including the kinase encoded by mutated D816V. It received Food and Drug Administration (FDA) approval in 2017 for treating SM-AHN, ASM, and MCL, and it has been found to improve quality of life and mediator-related symptoms in patients with advanced SM [9]. The gene discussed is KIT; the disease is systemic mastocytosis.